Open AccessP1376: LENALIDOMIDE–BASED MAINTENANCE AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK MULTIPLE MYELOMA
Author(s) -
Pasvolsky O.,
Milton D.,
Rauf M.,
Tanner M.,
Bashir Q.,
Srour S.,
Saini N.,
Ramdial J.,
Nieto Y.,
Lee H.,
Patel K.,
Kebriaei P.,
Thomas S.,
Weber D.,
Orlowski R.,
Shpall E.,
Champlin R.,
Qazilbash M.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000848364.06453.c1
Subject(s) - lenalidomide , medicine , multiple myeloma , oncology , hazard ratio , minimal residual disease , bortezomib , hematopoietic stem cell transplantation , regimen , transplantation , autologous stem cell transplantation , salvage therapy , maintenance therapy , surgery , chemotherapy , bone marrow , confidence interval